File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: LiverSCA 2.0: An Enhanced Comprehensive Cell Atlas for Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

TitleLiverSCA 2.0: An Enhanced Comprehensive Cell Atlas for Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Authors
Keywordshepatocellular carcinoma
intrahepatic cholangiocarcinoma
metabolic dysfunction-associated steatotic liver disease/steatohepatitis
Issue Date5-Mar-2025
PublisherMDPI
Citation
Cancers, 2025, v. 17, n. 5 How to Cite?
Abstract

Background: Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are two distinct types of primary liver cancer (PLC) characterized by considerable extents of cellular and molecular heterogeneities. We recently developed a web-based cell atlas called LiverSCA that possesses a user-friendly interface and comprehensive functionalities. It facilitates the exploration of gene expression patterns, cellular compositions, and intercellular communication within the microenvironments of liver and PLC tumors. Methods: To further enhance the documentation of data pinpointing different phenotypes/subtypes of liver and PLC, we extended the catalog of LiverSCA with additional datasets, e.g., ICC and metabolic dysfunction-associated steatotic liver disease/steatosis (MASLD/MASH). Results: The current enhanced version of the LiverSCA cell atlas encompasses six phenotypes (normal, HBV-HCC, HCV-HCC, non-viral HCC, ICC, and MASH), 63 patients, and over 248,000 cells. Furthermore, we have incorporated comparative visualization methods that allow users to simultaneously examine and compare gene expression levels between two different phenotypes. Conclusions: We are committed to the continuous development of LiverSCA and envision that it will serve as a valuable resource to support researchers in convenient investigations into the cellular and molecular landscapes of liver and PLC.


Persistent Identifierhttp://hdl.handle.net/10722/357667
ISSN
2023 Impact Factor: 4.5
2023 SCImago Journal Rankings: 1.391
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorSuoangbaji, Tina-
dc.contributor.authorLong, Renwen-
dc.contributor.authorNg, Irene Oi Lin-
dc.contributor.authorMak, Loey Lung Yi-
dc.contributor.authorHo, Daniel Wai Hung-
dc.date.accessioned2025-07-22T03:14:11Z-
dc.date.available2025-07-22T03:14:11Z-
dc.date.issued2025-03-05-
dc.identifier.citationCancers, 2025, v. 17, n. 5-
dc.identifier.issn2072-6694-
dc.identifier.urihttp://hdl.handle.net/10722/357667-
dc.description.abstract<p>Background: Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are two distinct types of primary liver cancer (PLC) characterized by considerable extents of cellular and molecular heterogeneities. We recently developed a web-based cell atlas called LiverSCA that possesses a user-friendly interface and comprehensive functionalities. It facilitates the exploration of gene expression patterns, cellular compositions, and intercellular communication within the microenvironments of liver and PLC tumors. Methods: To further enhance the documentation of data pinpointing different phenotypes/subtypes of liver and PLC, we extended the catalog of LiverSCA with additional datasets, e.g., ICC and metabolic dysfunction-associated steatotic liver disease/steatosis (MASLD/MASH). Results: The current enhanced version of the LiverSCA cell atlas encompasses six phenotypes (normal, HBV-HCC, HCV-HCC, non-viral HCC, ICC, and MASH), 63 patients, and over 248,000 cells. Furthermore, we have incorporated comparative visualization methods that allow users to simultaneously examine and compare gene expression levels between two different phenotypes. Conclusions: We are committed to the continuous development of LiverSCA and envision that it will serve as a valuable resource to support researchers in convenient investigations into the cellular and molecular landscapes of liver and PLC.</p>-
dc.languageeng-
dc.publisherMDPI-
dc.relation.ispartofCancers-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjecthepatocellular carcinoma-
dc.subjectintrahepatic cholangiocarcinoma-
dc.subjectmetabolic dysfunction-associated steatotic liver disease/steatohepatitis-
dc.titleLiverSCA 2.0: An Enhanced Comprehensive Cell Atlas for Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma-
dc.typeArticle-
dc.identifier.doi10.3390/cancers17050890-
dc.identifier.scopuseid_2-s2.0-86000490067-
dc.identifier.volume17-
dc.identifier.issue5-
dc.identifier.eissn2072-6694-
dc.identifier.isiWOS:001442274700001-
dc.identifier.issnl2072-6694-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats